In October 2007, Galapagos announced a multi-target alliance with Janssen Pharmaceutica NV, a Johnson & Johnson company, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis. Galapagos is responsible for the discovery and development of drug candidates through to clinical Proof of Concept, at which point Janssen will have an exclusive option to license each compound for further development and commercialization on a worldwide basis.
One of the programs in the alliance includes a novel target for inflammatory disorders that was identified and validated by Galapagos using its proprietary target discovery engine. Subsequent Galapagos research led to the discovery of GLPG1205, a first-in-class molecule for inflammatory disorders like inflammatory bowel disease. Galapagos will be responsible for execution of Phase 1 and Phase 2A studies with GLPG1205.
Galapagos announced that GLPG1205 has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study. The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205. The randomized, double-blind, placebo-controlled, single center study was conducted in 40 healthy volunteers in Belgium. In the first part of the study, single ascending doses were evaluated. In the second part, the new compound was administered daily for 14 days. The data shown in Phase 1 encourage Galapagos to progress GLPG1205 into a Phase 2A study in Inflammatory Bowel Disease (IBD).